Publications

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.

COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk None. and COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium None., (2022), Cell, 185, 916 - 938.e58

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.

Wei J. et al, (2022), Nat Med

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676

Symptoms and SARS-CoV-2 positivity in the general population in the UK.

Vihta K-D. et al, (2021), Clin Infect Dis

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population.

Wei J. et al, (2021), Nat Commun, 12

Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.

Wei J. et al, (2021), Nat Microbiol, 6, 1140 - 1149

The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers.

Lumley SF. et al, (2021), Clin Infect Dis, 73, e699 - e709

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Wei J. et al, (2021)

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Wei J. et al, (2021)

An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status.

Lumley SF. et al, (2021), Clin Infect Dis

Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.

Eyre DW. et al, (2021), Clin Microbiol Infect

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), Lancet, 397, 2049 - 2059

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Ahern DJ. et al, (2021)

Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections.

Eyre DW. et al, (2021), BMC Infect Dis, 21

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.

Lumley SF. et al, (2021), N Engl J Med, 384, 533 - 540

High-resolution 3D imaging uncovers organ-specific vascular control of tissue aging.

Chen J. et al, (2021), Sci Adv, 7

Decreased blood vessel density and endothelial cell subset dynamics during ageing of the endocrine system.

Chen J. et al, (2021), EMBO J, 40

Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey.

Pouwels KB. et al, (2021), Lancet Public Health, 6, e30 - e38

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.

National SARS-CoV-2 Serology Assay Evaluation Group None., (2020), Lancet Infect Dis, 20, 1390 - 1400

SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020.

Lumley SF. et al, (2020), Euro Surveill, 25

Cookies on this website

Publications